Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 8, 2017
Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that new data on RXDX-105 – a VEGFR-sparing, ...
September 8, 2017
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive ...
September 8, 2017
BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference
ALAMEDA, Calif.-- (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that ...
September 8, 2017
Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy in Preclinical Models of Duchenne Muscular Dystrophy
PARIS, Sept. 08, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, ...
September 7, 2017
OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio
NANTES, France-- (BUSINESS WIRE) -- Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today reported its consolidated half-year financial results as of June 30, ...
September 7, 2017
ABIVAX and Evotec Enter Into Strategic Collaboration to Develop Novel Antiviral Agents
Hamburg, Germany and Paris, France, 7th September 2017 at 7:30am (CEST) - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and ABIVAX (Euronext Paris: FR0012333284 ...
September 7, 2017
Zealand and Orbit Discovery enter into research collaboration
Zealand Pharma A/S ("Zealand") and Orbit Discovery Ltd ("Orbit") announce that they have entered into a multi-target research collaboration to identify novel peptide therapeutics using ...
September 7, 2017
BioLife Solutions to Present at September Investment Conferences
BOTHELL, Wash., Sept. 7, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and ...
September 7, 2017
Kamada to Present Corporate Overview at Two Investor Conferences in September
REHOVOT, Israel, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that Amir London, ...
September 7, 2017
TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma
SAN DIEGO, Sept. 07, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
September 7, 2017
BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference
RALEIGH, N.C., Sept. 7, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) presented three posters including results from an analysis of data which evaluated the ...
September 7, 2017
Rockwell Medical Appoints John G. Cooper to Board of Directors
WIXOM, Mich., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease ...
September 6, 2017
CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference
MONMOUTH JUNCTION, N.J., Sept. 6, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb®blood filter to prevent or treat deadly ...
September 6, 2017
Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
AUSTIN, Texas, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
September 6, 2017
Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories
CRANBURY, NJ, Sept. 6, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; "Palatin") announced today that it has entered into a collaboration and license agreement ...
September 6, 2017
MediWound’s NexoBrid® Highlighted in 43 Presentations at the 17th European Burns Association Congress
YAVNE, Israel, Sept. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe ...
September 6, 2017
Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that, based on recent FDA guidance, Ignyta has ...
September 6, 2017
HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference
TUCSON, Ariz., Sept. 06, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents and services for molecular profiling applications, today ...
September 6, 2017
Aimmune Therapeutics to Participate in Three Investor Conferences in September
BRISBANE, Calif. -- (BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune ...
September 6, 2017
Altimmune to Provide Corporate Update at the Rodman & Renshaw Global Investment Conference
GAITHERSBURG, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer ...
Page 130 of 153